title: Association of serum level of 25 hydroxy-vitamin D with prognostic factors for breast cancer.
abstract: OBJECTIVE
  In recent years, there has been considerable interest in whether vitamin D inhibits breast cancer development. Experimental studies have shown that vitamin D promotes cell differentiation and retards or terminates proliferation of breast cancer cells. However, there is little evidence supporting the association of vitamin D and prognosis of breast cancer.
  
  
  METHODS
  In this analytic-descriptive study, 119 female patients with histological proven breast cancer were recruited in Tabriz oncology clinics in a 15-month period of time. History of chemotherapy, radiotherapy or receiving vitamin D/Ca supplements and presence of other malignancies were exclusion criteria. Serum level of 25 hydroxy vitamin D (25(OH)D) was measured in all patients.
  
  
  RESULTS
  One hundred and nineteen patients with a mean age of 50.4∓12.6 (26-76) years were enrolled in the study. Metastasis was present in 21.8% of the cases. Stage of tumor was I, II, III and IV in 11, 56, 26 and 26 patients, respectively. The Tumor grade was low in 37 cases, intermediate in 46 cases, and high in 36 cases. The P53, Ki-67, HER2, ER and PR were positive in 30.3%, 49.6%, 17.6%, 61.2% and 55.5% of the patients, respectively. The mean serum level of 25(OH)D was 15.7∓17.8 (4-122) ng/ml, deficient in 66 cases, insufficient in 36 cases and normal level in 17 cases. The median level of 25(OH)D was lower in the P53+ group in a borderline trend (17.3 vs. 13.6 ng/ml; p=0.07). The median level of 25(OH)D was significantly higher in the patients with metastasis, as well (27.7 vs. 12.0 ng/ml; p=0.03). There was no significant association between the serum level of 25(OH)D and other studied parameters.
  
  
  CONCLUSIONS
  Based on our findings, there may be an association between the serum level of 25(OH)D and prognosis of breast cancer.
authors: Hematology and Oncology Research Center, Shahid Ghazi Tabatabai Hospital, and Physiology Department, Tabriz Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Iraj Asvadi
authors: IA
authors: Kermani
authors: Habibeh Taghavi
authors: HT
authors: Kojidi
authors: Jalil Vaez
authors: JV
authors: Gharamaleki
authors: Zohreh
authors: Z
authors: Sanaat
authors: Jamal Eivazi
authors: JE
authors: Ziaei
authors: Ali
authors: A
authors: Esfahani
authors: Sharareh
authors: S
authors: Seifi
authors: Morteza
authors: M
authors: Ghojazadeh
authors: Roya
authors: R
authors: Dolatkhah
authors: Atabak Asvadi
authors: AA
authors: Kermani
authors: Elnaz Ghaemi
authors: EG
authors: Rad
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007492:Iran; D019394:Ki-67 Antigen / Q000097:blood; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D011960:Receptors, Estrogen / Q000097:blood; D011980:Receptors, Progesterone / Q000097:blood; D016159:Tumor Suppressor Protein p53 / Q000097:blood; D014807:Vitamin D / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use
chemical_list: D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; D014807:Vitamin D; C495901:TP53 protein, human; C104450:25-hydroxyvitamin D; C508053:ERBB2 protein, human